Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, itraq

Clinical Proteomics

Volumn 10, Issue 1, 2013, Pages

  Kristjansdottir, Björg ^a   Levan, Kristina ^a   Partheen, Karolina ^a   Carlsohn, Elisabet ^b   Sundfeldt, Karin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Itraq; Mass spectrometry; Ovarian adenocarcinoma; Ovarian cyst fluid; Tumor biomarker

Indexed keywords

ASTACIN LIKE METALLOENDOPEPTIDASE; METALLOPROTEINASE; SERUM AMYLOID A; SERUM AMYLOID A4; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYST FLUID; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INVESTIGATIVE PROCEDURES; ISOBARIC TAG FOR RELATIVE AND ABSOLUTE QUANTITATION METHOD; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RNA SEQUENCE; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION; VALIDATION PROCESS;

EID: 84903724479     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-10-4     Document Type: Article

References (47)

1. Social Styrelsen CfEoTSNBoHaW: Causes of death 2008. The Swedish National Board of Health and Welfare; 2010. www.socialstyrelsen.se/statistik/ statistikefteramne/cancer.
2. Kristjansdottir B, Partheen K, Fung ET, Marcickiewicz J, Yip C, Brannstrom M, Sundfeldt K: Ovarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers. Clinical Proteomics 2012, 9(1):14.
3. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U: Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S161-S192.
4. van Nagell JR Jr, De Priest PD, Ueland FR, De Simone CP, Cooper AL, McDonald JM, Pavlik EJ, Kryscio RJ: Ovarian cancer screening with annual transvaginal sonography: findings of 25, 000 women screened. Cancer 2007, 109(9):1887-1896. (Pubitemid 46668555)
5. MacDonald ND, Jacobs IJ: Is there a place for screening in ovarian cancer? Eur J Obstet Gynecol Reprod Biol 1999, 82(2):155-157. (Pubitemid 29074312)
6. ShihIe M, Kurman RJ: Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin Cancer Res: An Official J Am Assoc Cancer Res 2005, 11(20):7273-7279. (Pubitemid 41507684)
7. Markman M: The role of CA-125 in the management of ovarian cancer. Oncologist 1997, 2(1):6-9. (Pubitemid 27163434)
8. Markman M, Federico M, Liu PY, Hannigan E, Alberts D: Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, 103(1):195-198. (Pubitemid 44389869)
9. Meyer T, Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 2000, 82(9):1535-1538. (Pubitemid 30204358)
10. Kolwijck E, Span PN, Thomas CM, Bulten J, Sweep FC, Massuger LF: Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. Oncol Rep 2010, 23(2):579-584.
11. Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH, Massuger LF: GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2009, 18(8):2176-2181.
12. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993, 85(21):1748-1751. (Pubitemid 23320845)
13. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010, 117(3):440-445.
14. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, Di Silvestro P, Granai CO, et al: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108(2):402-408. (Pubitemid 351174295)
15. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63(13):3695-3700. (Pubitemid 36793054)
16. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008, 110(3):374-382.
17. Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C: Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand 2009, 88(1):18-26.
18. Ivarsson K, Runesson E, Sundfeldt K, Haeger M, Hedin L, Janson PO, Brannstrom M: The chemotactic cytokine interleukin-8-a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncol 1998, 71(3):420-423. (Pubitemid 29022330)
19. Sundfeldt K, Ivarsson K, Rask K, Haeger M, Hedin L, Brannstrom M: Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res 2001, 21(1A):65-70. (Pubitemid 32267626)
20. Boylan KL, Andersen JD, Anderson LB, Higgins L, Skubitz AP: Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum. Proteome Sci 2010, 8:31.
21. Gagne JP, Ethier C, Gagne P, Mercier G, Bonicalzi ME, Mes-Masson AM, Droit A, Winstall E, Isabelle M, Poirier GG: Comparative proteome analysis of human epithelial ovarian cancer. Proteome science 2007, 5:16.
22. Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Aebersold R, Lee H, et al: Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res 2012, 11(5):2876-2889.
23. Ryu JK, Woo SM, Hwang JH, Jeong JB, Yoon YB, Park IA, Han JK, Kim YT: Cyst fluid analysis for the differential diagnosis of pancreatic cysts. Diagn Cytopathol 2004, 31(2):100-105. (Pubitemid 38989277)
24. Toyama A, Suzuki A, Shimada T, Aoki C, Aoki Y, Umino Y, Nakamura Y, Aoki D, Sato TA: Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acidbinding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Sci 2012, 103(4):747-755.
25. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S: Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. The J histochemistry and Cytochemistry: Official J Histochemistry Soc 2006, 54(1):63-73. (Pubitemid 43049416)
26. Michaeli A, Finci-Yeheskel Z, Dishon S, Linke RP, Levin M, Urieli-Shoval S: Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. Biochem Biophys Res Commun 2008, 368(2):368-373.
27. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. The J Histochemistry and Cytochemistry: Official J Histochemistry Soc 2010, 58(11):1015-1023.
28. Quesada V, Sanchez LM, Alvarez J, Lopez-Otin C: Identification and characterization of human and mouse ovastacin: A novel metalloproteinase similar to hatching enzymes from arthropods, birds, amphibians, and fish. J Biol Chem 2004, 279(25):26627-26634. (Pubitemid 38798820)
29. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009, 115(1):112-120.
30. Cohen M, Petignat P: Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells. Cancer Lett 2011, 309(1):104-109.
31. Jakobsen CG, Rasmussen N, Laenkholm AV, Ditzel HJ: Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res 2007, 67(19):9507-9517. (Pubitemid 47535941)
32. Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B, et al: Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 2006, 45(31):9434-9444. (Pubitemid 44223248)
33. Parker D, Bradley C, Bogle SM, Lay J, Masood M, Hancock AK, Naylor B, Price JJ: Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994, 101(10):888-893. (Pubitemid 24316739)
34. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS: Measurement of the systemic inflammatory response predicts cancerspecific and non-cancer survival in patients with cancer. Nutr Cancer 2001, 41(1-2):64-69. (Pubitemid 34666222)
35. Cortesi L, Rossi E, Della Casa L, Barchetti A, Nicoli A, Piana S, Abrate M, La Sala GB, Federico M, Iannone A: Protein expression patterns associated with advanced stage ovarian cancer. Electrophoresis 2011, 32(15):1992-2003.
36. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP: Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 2009, 18(2-3):47-56.
37. Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, Lee C: Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009, 8(3):1368-1379.
38. Ott HW, Lindner H, Sarg B, Mueller-Holzner E, Abendstein B, Bergant A, Fessler S, Schwaerzler P, Zeimet A, Marth C, et al: Calgranulins in cystic fluid and serum from patients with ovarian carcinomas. Cancer Res 2003, 63(21):7507-7514. (Pubitemid 37413495)
39. Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A: The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol 2010, 151(1):3-9.
40. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirmacher P, Friess H, Kleeff J: Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 2007, 9(1):8-17. (Pubitemid 46203930)
41. Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y, Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 2011, 17(15):2028-2036.
42. Hogdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL, Risum S, Lundvall L, Yip C, Pedersen AT, et al: A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011, 123(2):308-313.
43. Maines-Bandiera S, Woo MM, Borugian M, Molday LL, Hii T, Gilks B, Leung PC, Molday RS, Auersperg N: Oviductal glycoprotein (OVGP1, MUC9): A differentiation-based mucin present in serum of women with ovarian cancer. Int J Gynecol Cancer 2010, 20(1):16-22.
44. Biade S, Marinucci M, Schick J, Roberts D, Workman G, Sage EH, O'Dwyer PJ, Livolsi VA, Johnson SW: Gene expression profiling of human ovarian tumours. Br J Cancer 2006, 95(8):1092-1100. (Pubitemid 44606838)
45. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: Novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010, 11(1):111-116.
46. Carlsohn E, Nystrom J, Karlsson H, Svennerholm AM, Nilsson CL: Characterization of the outer membrane protein profile from diseaserelated Helicobacter pylori isolates by subcellular fractionation and nano-LC FT-ICR MS analysis. J Proteome Res 2006, 5(11):3197-3204. (Pubitemid 44749237)
47. Zhu Y, Brannstrom M, Janson PO, Sundfeldt K: Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer J Int Du Cancer 2006, 118(8):1884-1891.